Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure

被引:5
作者
Gerlach, Raquel F. [1 ]
Tanus-Santos, Jose E.
机构
[1] Univ Sao Paulo, Dent Sch Ribeirao Preto, Dept Morphol Estomatol & Physiol, BR-05508 Sao Paulo, Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-05508 Sao Paulo, Brazil
关键词
D O I
10.1016/j.ahj.2006.04.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:1
相关论文
共 8 条
[1]   Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure [J].
George, J ;
Patal, S ;
Wexler, D ;
Roth, A ;
Sheps, D ;
Keren, G .
AMERICAN HEART JOURNAL, 2005, 150 (03) :484-487
[2]   Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities [J].
Gerlach, RF ;
Uzuelli, JA ;
Souza-Tarla, CD ;
Tanus-Santos, JE .
ANALYTICAL BIOCHEMISTRY, 2005, 344 (01) :147-149
[3]  
Jung K, 1998, CLIN CHEM, V44, P1060
[4]   Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood [J].
Jung, K ;
Lein, M ;
Laube, C ;
Lichtinghagen, R .
CLINICA CHIMICA ACTA, 2001, 314 (1-2) :241-244
[5]   Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma [J].
Makowski, GS ;
Ramsby, ML .
ANALYTICAL BIOCHEMISTRY, 2003, 322 (02) :283-286
[6]   Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities [J].
Souza-Tarla, CD ;
Uzuelli, JA ;
Machado, AA ;
Gerlach, RF ;
Tanus-Santos, JE .
CLINICAL BIOCHEMISTRY, 2005, 38 (05) :410-414
[7]   Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease [J].
Tanus-Santos, JE ;
Gerlach, RF .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (03) :789-789
[8]  
TANUSSANTOS JE, 2005, ARTERIOSCLER THROMB, V25, pE27